Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2016 May 27;34(5):213-9.
doi: 10.3109/07357907.2016.1174257. Epub 2016 Apr 29.

A Phase II Study of the Combination of Bevacizumab, Pertuzumab, and Octreotide LAR for Patients With Advanced Neuroendocrine Cancers

Affiliations
Clinical Trial

A Phase II Study of the Combination of Bevacizumab, Pertuzumab, and Octreotide LAR for Patients With Advanced Neuroendocrine Cancers

Johanna C Bendell et al. Cancer Invest. .

Abstract

Purpose: To evaluate efficacy and safety of bevacizumab, pertuzumab, and octreotide depot for advanced neuroendocrine tumors.

Methods: Patients received bevacizumab 15 mg/kg and pertuzumab 420 mg IV q21 days with octreotide depot 30 mg IM q28 days.

Results: Toxicities in 43 patients included diarrhea (63%), fatigue (63%), hypertension (44%), and nausea (44%). Reversible G3 hypertension (26%) and LVEF decline (9%) occurred. 7/43 patients achieved objective response (typical carcinoid, 5; pancreatic NET, 2). Median PFS and OS were 6.5 and 26.4 months, respectively.

Discussion: Bevacizumab, pertuzumab, and octreotide depot was well-tolerated with a 16% ORR. Results in the well-differentiated carcinoid tumors are thought provoking.

Keywords: Angiogenesis; Monoclonal antibodies; Pancreatic cancer.

Similar articles

See all similar articles

Cited by 4 articles

Publication types

MeSH terms

LinkOut - more resources

Feedback